Effect of Beta-Blocker Dose on Survival after Acute Myocardial Infarction

Journal of the American College of Cardiology

Volumn 66, Issue 13, 2015, Pages 1431-1441

  Goldberger, Jeffrey J ^a   Bonow, Robert O ^a   Cuffe, Michael ^b   Liu, Lei ^a   Rosenberg, Yves ^c   Shah, Prediman K ^d   Smith, Sidney C ^e   Subačius, Haris ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Hospital Corporation of America   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

adrenergic beta antagonists; follow up studies; registries; survival analysis

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; METOPROLOL; PROPRANOLOL;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL EVALUATION; DISEASE REGISTRY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; PROPENSITY SCORE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL; TREATMENT OUTCOME; AGED; CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIAL; REGISTER; SURVIVAL RATE; TRENDS; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; REGISTRIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84942115083     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.07.047     Document Type: Article

References (40)

1. K.K. Teo, S. Yusuf, and C.D. Furberg Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials JAMA 270 1993 1589 1595
2. N. Freemantle, J. Cleland, P. Young, and et al. β blockade after myocardial infarction: systematic review and meta regression analysis BMJ 318 1999 1730 1737
3. S.S. Gottlieb, R.J. McCarter, and R.A. Vogel Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction N Engl J Med 339 1998 489 497
4. H.M. Krumholz, M.J. Radford, Y. Wang, and et al. National use and effectiveness of β-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project JAMA 280 1998 623 629
5. S.B. Soumerai, T.J. McLaughlin, D. Spiegelman, and et al. Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction JAMA 277 1997 115 121
6. P.T. O'Gara, F.G. Kushner, D.D. Ascheim, and et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78 e140
7. J.L. Anderson, C.D. Adams, E.M. Antman, and et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J Am Coll Cardiol 50 2007 652 726
8. S.V. Arnold, J.A. Spertus, F.A. Masoudi, and et al. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction J Am Coll Cardiol 62 2013 1791 1801
9. J.J. Goldberger, R.O. Bonow, M. Cuffe, et al. PACE-MI Investigators β-blocker use following myocardial infarction: low prevalence of evidence-based dosing Am Heart J 160 2010 435 442
10. M. Cucherat Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials Eur Heart J 28 2007 3012 3019
11. J.K. Kjekshus Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials Am J Cardiol 57 1986 43F 49F
12. J.J. Goldberger, R.O. Bonow, M. Cuffe, and et al. Post-myocardial infarction β-blocker therapy: the bradycardia conundrum. Rationale and design for the Pacemaker & β-Blocker Therapy Post-MI (PACE-MI) trial Am Heart J 155 2008 455 464
13. The MIAMI Trial Research Group Metroprolol in Acute Myocardial Infarction (MIAMI): a randomized placebo-controlled international trial Eur Heart J 6 1985 199 226
14. A. Hjalmarson, D. Elmfeldt, J. Herlitz, and et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial Lancet 2 1981 823 827
15. The CAPRICORN Investigators Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial Lancet 357 2001 1385 1390
16. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results JAMA 247 1982 1707 1714
17. Norwegian Multicenter Study Group Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction N Engl J Med 304 1981 801 807
18. CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial Lancet 353 1999 9 13
19. S. Viskin, I. Kitzis, E. Lev, and et al. Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice J Am Coll Cardiol 25 1995 1327 1332
20. Z.M. Chen, H.C. Pan, Y.P. Chen, et al. for the COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1622 1632
21. S. Bangalore, H. Makani, M. Radford, and et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials Am J Med 127 2014 939 953
22. C. Andersson, D. Shilane, A.S. Go, and et al. β-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease J Am Coll Cardiol 64 2014 247 252
23. H.V. Barron, S. Viskin, R.J. Lundstrom, and et al. β-blocker dosages and mortality after myocardial infarction: data from a large health maintenance organization Arch Intern Med 158 1998 449 453
24. C.W. Siu, V. Pong, M.H. Jim, and et al. β-blocker in post-myocardial infarct survivors with preserved left ventricular systolic function Pacing Clin Electrophysiol 33 2010 675 680
25. J. Wikstrand, A. Hjalmarson, F. Waagstein, et al. for the MERIT-HF Study Group Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF) J Am Coll Cardiol 40 2002 491 498
26. M. Metra, C. Torp-Pedersen, K. Swedberg, and et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial Eur Heart J 26 2005 2259 2268
27. D. Dobre, D.J. van Veldhuisen, G. Mordenti, et al. for the SENIORS Investigators Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial Am Heart J 154 2007 109 115
28. F.A. McAlister, N. Wiebe, J.A. Ezekowitz, and et al. Meta-analysis: β-blocker dose, heart rate reduction, and death in patients with heart failure Ann Intern Med 150 2009 784 794
29. V.A. Fonseca Effects of beta-blockers on glucose and lipid metabolism Curr Med Res Opin 26 2010 615 629
30. G. Olsson, J. Wikstrand, I. Warnold, and et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials Eur Heart J 13 1992 28 32
31. M. Hulleman, J. Berdowski, J.R. de Groot, and et al. Implantable cardioverter-defibrillators have reduced the incidence of resuscitation for out-of-hospital cardiac arrest caused by lethal arrhythmias Circulation 126 2012 815 821
32. S.T. Youngquist, A.H. Kaji, and J.T. Niemann Beta-blocker use and the changing epidemiology of out-of-hospital cardiac arrest rhythms Resuscitation 76 2008 376 380
33. P.E. Bloch Thomsen, C. Jons, M.J. Raatikainen, et al. for the Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA) Study Group Long-term recording of cardiac arrhythmias with an implantable cardiac monitor in patients with reduced ejection fraction after acute myocardial infarction: the Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA) study Circulation 122 2010 1258 1264
34. D. Nakatani, Y. Sakata, S. Suna, et al. for the Osaka Acute Coronary Insufficiency Study (OACIS) Investigators Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era Am J Cardiol 111 2013 457 464
35. W.N. Liu, K.L. Fu, H.Y. Gao, and et al. β1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to β-blocker therapy and prognosis PLoS One 7 2012 e37659
36. 2-adrenergic receptor genotype and survival among patients receiving β-blocker therapy after an acute coronary syndrome JAMA 294 2005 1526 1533
37. S. Cresci, G.W. Dorn II, P.G. Jones, and et al. Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific manner J Am Coll Cardiol 60 2012 898 907
38. R.G. Aleong, W.H. Sauer, A.D. Robertson, and et al. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure Circ Arrhythm Electrophysiol 6 2013 137 143
39. R. Koytchev, R.G. Alken, V. Vlahov, and et al. Influence of the cytochrome P4502D6∗4 allele on the pharmacokinetics of controlled-release metoprolol Eur J Clin Pharmacol 54 1998 469 474
40. R. Ismail, and L.K. Teh The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients J Clin Pharm Ther 31 2006 99 109